Altretamine(Synonyms: 六甲蜜胺; ENT-50852; RB-1515; WR-95704)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Altretamine (Synonyms: 六甲蜜胺; ENT-50852; RB-1515; WR-95704) 纯度: 99.64%

Altretamine 是一种烷化剂 (alkylator)，具有抗肿瘤活性。

Altretamine(Synonyms: 六甲蜜胺; ENT-50852; RB-1515; WR-95704)

Altretamine Chemical Structure

CAS No. : 645-05-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥660 In-stock
100 mg ￥600 In-stock
500 mg ￥1188 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Altretamine 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • NMPA-Approved Drug Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Altretamine is an alkylating antineoplastic agent.

体外研究
(In Vitro)

Altretamine is an antineoplastic agent[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearing MV522 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

210.28

Formula

C9H18N6
CAS 号

645-05-6
中文名称

六甲蜜胺
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 8.33 mg/mL (39.61 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.7556 mL 23.7778 mL 47.5556 mL
5 mM 0.9511 mL 4.7556 mL 9.5111 mL
10 mM 0.4756 mL 2.3778 mL 4.7556 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 0.83 mg/mL (3.95 mM); Clear solution

    此方案可获得 ≥ 0.83 mg/mL (3.95 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 0.83 mg/mL (3.95 mM); Clear solution

    此方案可获得 ≥ 0.83 mg/mL (3.95 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
Animal Administration
[1]

Mice[1]
Balb/c nu/nu 4 week old female mice weighing 18-22 g, receive s.c. injections of 8-10 million MV522 cells. Altretamine is administered i.p. three times a week for 3 weeks, starting on day 10 after tumor implantation. Tumor size is measured in two perpendicular diameters and tumor weight (TW) estimated according to the formula: w = [(width)2 × length/2]. Altretamine is prepared as stock solutions of 1-10 mg/mL in 40% DMSO/normal saline and diluted with 10% DMSO/normal saline as required[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务